FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Molecular pharmacology1998; 53(1); 112-122; doi: 10.1124/mol.53.1.112

Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases.

Abstract: To understand the role of glycosylation in the circulation of cholinesterases, we compared the mean residence time of five tissue-derived and two recombinant cholinesterases (injected intravenously in mice) with their oligosaccharide profiles. Monosaccharide composition analysis revealed differences in the total carbohydrate, galactose, and sialic acid contents. The molar ratio of sialic acid to galactose residues on tetrameric human serum butyrylcholinesterase, recombinant human butyrylcholinesterase, and recombinant mouse acetylcholinesterase was found to be approximately 1.0. For Torpedo californica acetylcholinesterase, monomeric and tetrameric fetal bovine serum acetylcholinesterase, and equine serum butyrylcholinesterase, this ratio was approximately 0.5. However, the circulatory stability of cholinesterases could not be correlated with the sialic acid-to-galactose ratio. Fractionation of the total pool of oligosaccharides obtained after neuraminidase digestion revealed one major oligosaccharide for human serum butyrylcholinesterase and three or four major oligosaccharides in other cholinesterases. The glycans of tetrameric forms of plasma cholinesterases (human serum butyrylcholinesterase, fetal bovine serum acetylcholinesterase, and equine serum butyrylcholinesterase) clearly demonstrated a reduced heterogeneity and higher maturity compared with glycans of monomeric fetal bovine serum acetylcholinesterase, dimeric tissue-derived T. californica acetylcholinesterase, and recombinant cholinesterases. T. californica acetylcholinesterase, recombinant cholinesterases, and monomeric fetal bovine serum acetylcholinesterase showed a distinctive shorter mean residence time (44-304 min) compared with tetrameric forms of plasma cholinesterases (1902-3206 min). Differences in the pharmacokinetic parameters of cholinesterases seem to be due to the combined effect of the molecular weight and charge- and size-based heterogeneity in glycans.
Get Full Text
Publication Date: 1998-01-28 PubMed ID: 9443938DOI: 10.1124/mol.53.1.112Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study examines the role of glycosylation in the circulation of cholinesterases, by comparing the residence time of several tissue-derived and recombinant cholinesterases with their oligosaccharide profiles. The researchers found that differences in pharmacokinetic parameters of cholinesterases appear to be associated with the combined effect of molecular weight and heterogeneity of glycans.

Objective and Methodology

  • This research seeks to understand how glycosylation influences the circulation of cholinesterases. This is achieved by comparing the mean residence time (the time that a drug stays in the body before being metabolized or eliminated) of five tissue-derived and two recombinant cholinesterases. All substances were injected intravenously in mice and their corresponding oligosaccharide profiles analyzed.

Results

  • An analysis of the composition of monosaccharides revealed significant differences in the total carbohydrate, galactose, and sialic acid contents of different cholinesterases.
  • The molar ratio of sialic acid to galactose residues reported relatively similar values for some factorials: around 1.0 for tetrameric human serum butyrylcholinesterase, recombinant human butyrylcholinesterase, and recombinant mouse acetylcholinesterase, and about 0.5 for Torpedo californica acetylcholinesterase, monomeric and tetrameric fetal bovine serum acetylcholinesterase, and equine serum butyrylcholinesterase.
  • However, it wasn’t possible to establish a link between a cholinesterase’s circulatory stability and its sialic acid-to-galactose ratio.
  • The fractionation of the total pool of oligosaccharides after digestion with neuraminidase revealed one major oligosaccharide for human serum butyrylcholinesterase and between three or four major oligosaccharides in other cholinesterases.
  • In comparison to others, the glycans of tetrameric forms of plasma cholinesterases showed a reduced heterogeneity and a higher maturity.
  • Differences were found in the mean residence time of different cholinesterases with some having shorter residence times (44-304 minutes) than the tetrameric forms of plasma cholinesterases (1902-3206 minutes).

Conclusion

  • Particularly, the variations in the pharmacokinetic parameters of cholinesterases seem to be influenced by a combination of factors: the molecular weight and the heterogeneity (based on charge and size) in glycans.
  • This research provides valuable insight into the role of glycosylation in the pharmacokinetics of cholinesterases, which could be pivotal for understanding and improving drug delivery mechanisms and effectiveness.

Cite This Article

APA
Saxena A, Ashani Y, Raveh L, Stevenson D, Patel T, Doctor BP. (1998). Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol Pharmacol, 53(1), 112-122. https://doi.org/10.1124/mol.53.1.112

Publication

Molecular pharmacology
ISSN: 0026-895X
NlmUniqueID: 0035623
Country: United States
Language: English
Volume: 53
Issue: 1
Pages: 112-122

Researcher Affiliations

Saxena, A
  • Division of Biochemistry, Walter Reed Army Institute of Research, Washington D. C. 20307-5100, USA.
Ashani, Y
    Raveh, L
      Stevenson, D
        Patel, T
          Doctor, B P

            MeSH Terms

            • Acetylcholinesterase / blood
            • Acetylcholinesterase / pharmacokinetics
            • Animals
            • Butyrylcholinesterase / blood
            • Butyrylcholinesterase / pharmacokinetics
            • CHO Cells
            • Cattle
            • Centrifugation, Density Gradient
            • Cholinesterases / analysis
            • Cholinesterases / blood
            • Cholinesterases / pharmacokinetics
            • Cricetinae
            • Enzyme Stability
            • Glycosylation
            • Horses
            • Humans
            • Injections, Intravenous
            • Mice
            • Oligosaccharides / analysis
            • Oligosaccharides / metabolism
            • Recombinant Proteins / pharmacokinetics
            • Torpedo

            Citations

            This article has been cited 23 times.
            1. Leung MR, Zeev-Ben-Mordehai T. Cryo-electron microscopy of cholinesterases, present and future. J Neurochem 2021 Sep;158(6):1236-1243.
              doi: 10.1111/jnc.15245pubmed: 33222205google scholar: lookup
            2. Lockridge O, David E, Schopfer LM, Masson P, Brazzolotto X, Nachon F. Purification of recombinant human butyrylcholinesterase on Hupresin®. J Chromatogr B Analyt Technol Biomed Life Sci 2018 Dec 1;1102-1103:109-115.
              doi: 10.1016/j.jchromb.2018.10.026pubmed: 30384187google scholar: lookup
            3. Corbin JM, Kailemia MJ, Cadieux CL, Alkanaimsh S, Karuppanan K, Rodriguez RL, Lebrilla CB, Cerasoli DM, McDonald KA, Nandi S. Purification, characterization, and N-glycosylation of recombinant butyrylcholinesterase from transgenic rice cell suspension cultures. Biotechnol Bioeng 2018 May;115(5):1301-1310.
              doi: 10.1002/bit.26557pubmed: 29411865google scholar: lookup
            4. Terekhov SS, Smirnov IV, Shamborant OG, Bobik TV, Ilyushin DG, Murashev AN, Dyachenko IA, Palikov VA, Knorre VD, Belogurov AA, Ponomarenko NA, Kuzina ES, Genkin DD, Masson P, Gabibov AG. Chemical Polysialylation and In Vivo Tetramerization Improve Pharmacokinetic Characteristics of Recombinant Human Butyrylcholinesterase-Based Bioscavengers. Acta Naturae 2015 Oct-Dec;7(4):136-41.
              pubmed: 26798501
            5. Schneider JD, Marillonnet S, Castilho A, Gruber C, Werner S, Mach L, Klimyuk V, Mor TS, Steinkellner H. Oligomerization status influences subcellular deposition and glycosylation of recombinant butyrylcholinesterase in Nicotiana benthamiana. Plant Biotechnol J 2014 Sep;12(7):832-9.
              doi: 10.1111/pbi.12184pubmed: 24618259google scholar: lookup
            6. Fang L, Hou S, Xue L, Zheng F, Zhan CG. Amino-acid mutations to extend the biological half-life of a therapeutically valuable mutant of human butyrylcholinesterase. Chem Biol Interact 2014 May 5;214:18-25.
              doi: 10.1016/j.cbi.2014.02.007pubmed: 24582612google scholar: lookup
            7. Schneider JD, Castilho A, Neumann L, Altmann F, Loos A, Kannan L, Mor TS, Steinkellner H. Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue. Biotechnol J 2014 Apr;9(4):501-10.
              doi: 10.1002/biot.201300229pubmed: 24130173google scholar: lookup
            8. Ilyushin DG, Smirnov IV, Belogurov AA Jr, Dyachenko IA, Zharmukhamedova TIu, Novozhilova TI, Bychikhin EA, Serebryakova MV, Kharybin ON, Murashev AN, Anikienko KA, Nikolaev EN, Ponomarenko NA, Genkin DD, Blackburn GM, Masson P, Gabibov AG. Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc Natl Acad Sci U S A 2013 Jan 22;110(4):1243-8.
              doi: 10.1073/pnas.1211118110pubmed: 23297221google scholar: lookup
            9. Biberoglu K, Schopfer LM, Tacal O, Lockridge O. The proline-rich tetramerization peptides in equine serum butyrylcholinesterase. FEBS J 2012 Oct;279(20):3844-58.
              doi: 10.1111/j.1742-4658.2012.08744.xpubmed: 22889087google scholar: lookup
            10. Masson P, Rochu D. Catalytic bioscavengers against toxic esters, an alternative approach for prophylaxis and treatments of poisonings. Acta Naturae 2009 Apr;1(1):68-79.
              pubmed: 22649587
            11. Geyer BC, Kannan L, Garnaud PE, Broomfield CA, Cadieux CL, Cherni I, Hodgins SM, Kasten SA, Kelley K, Kilbourne J, Oliver ZP, Otto TC, Puffenberger I, Reeves TE, Robbins N 2nd, Woods RR, Soreq H, Lenz DE, Cerasoli DM, Mor TS. Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents. Proc Natl Acad Sci U S A 2010 Nov 23;107(47):20251-6.
              doi: 10.1073/pnas.1009021107pubmed: 21059932google scholar: lookup
            12. Gao Y, Brimijoin S. Lasting reduction of cocaine action in neostriatum--a hydrolase gene therapy approach. J Pharmacol Exp Ther 2009 Aug;330(2):449-57.
              doi: 10.1124/jpet.109.152231pubmed: 19478136google scholar: lookup
            13. Pan Y, Muzyka JL, Zhan CG. Model of human butyrylcholinesterase tetramer by homology modeling and dynamics simulation. J Phys Chem B 2009 May 7;113(18):6543-52.
              doi: 10.1021/jp8114995pubmed: 19402731google scholar: lookup
            14. Woods RR, Geyer BC, Mor TS. Hairy-root organ cultures for the production of human acetylcholinesterase. BMC Biotechnol 2008 Dec 23;8:95.
              doi: 10.1186/1472-6750-8-95pubmed: 19105816google scholar: lookup
            15. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact 2008 Sep 25;175(1-3):83-7.
              doi: 10.1016/j.cbi.2008.04.024pubmed: 18514640google scholar: lookup
            16. Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M, Bilodeau AS, Bellemare A, Côté M, Herskovits P, Touati M, Turcotte C, Valeanu L, Lemée N, Wilgus H, Bégin I, Bhatia B, Rao K, Neveu N, Brochu E, Pierson J, Hockley DK, Cerasoli DM, Lenz DE, Karatzas CN, Langermann S. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci U S A 2007 Aug 21;104(34):13603-8.
              doi: 10.1073/pnas.0702756104pubmed: 17660298google scholar: lookup
            17. Evron T, Geyer BC, Cherni I, Muralidharan M, Kilbourne J, Fletcher SP, Soreq H, Mor TS. Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath. FASEB J 2007 Sep;21(11):2961-9.
              doi: 10.1096/fj.07-8112compubmed: 17475919google scholar: lookup
            18. Lockridge O, Schopfer LM, Winger G, Woods JH. LARGE SCALE PURIFICATION OF BUTYRYLCHOLINESTERASE FROM HUMAN PLASMA SUITABLE FOR INJECTION INTO MONKEYS; A POTENTIAL NEW THERAPEUTIC FOR PROTECTION AGAINST COCAINE AND NERVE AGENT TOXICITY. J Med Chem Biol Radiol Def 2005 Jul 1;3:nihms5095.
              doi: 10.1901/jaba.2005.3-nihms5095pubmed: 16788731google scholar: lookup
            19. Cohen O, Kronman C, Velan B, Shafferman A. Amino acid domains control the circulatory residence time of primate acetylcholinesterases in rhesus macaques (Macaca mulatta). Biochem J 2004 Feb 15;378(Pt 1):117-28.
              doi: 10.1042/BJ20031305pubmed: 14575524google scholar: lookup
            20. Cohen O, Kronman C, Chitlaru T, Ordentlich A, Velan B, Shafferman A. Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity. Biochem J 2001 Aug 1;357(Pt 3):795-802.
              doi: 10.1042/0264-6021:3570795pubmed: 11463350google scholar: lookup
            21. Chitlaru T, Kronman C, Velan B, Shafferman A. Effect of human acetylcholinesterase subunit assembly on its circulatory residence. Biochem J 2001 Mar 15;354(Pt 3):613-25.
              doi: 10.1042/0264-6021:3540613pubmed: 11237866google scholar: lookup
            22. Masson P, Cléry C, Guerra P, Redslob A, Albaret C, Fortier PL. Hydration change during the aging of phosphorylated human butyrylcholinesterase: importance of residues aspartate-70 and glutamate-197 in the water network as probed by hydrostatic and osmotic pressures. Biochem J 1999 Oct 15;343 Pt 2(Pt 2):361-9.
              pubmed: 10510301
            23. Chitlaru T, Kronman C, Zeevi M, Kam M, Harel A, Ordentlich A, Velan B, Shafferman A. Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem J 1998 Dec 15;336 ( Pt 3)(Pt 3):647-58.
              doi: 10.1042/bj3360647pubmed: 9841877google scholar: lookup
            Subscribe to our newsletter
            Join 99,824 horse owners like you who receive our email updates on horse health and nutrition.